S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Forecast, Price & News

$147.12
-0.58 (-0.39%)
(As of 06/2/2023 ET)
Compare
Today's Range
$146.60
▼
$148.65
50-Day Range
$136.30
▼
$153.10
52-Week Range
$104.50
▼
$153.10
Volume
1,411 shs
Average Volume
3,613 shs
Market Capitalization
N/A
P/E Ratio
180.29
Dividend Yield
1.90%
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest

AstraZeneca MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.30mentions of AstraZeneca in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.96 out of 5 stars

See Top Rated MarketRank™ Stocks Here

AZNCF stock logo

About AstraZeneca (OTCMKTS:AZNCF) Stock

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZNCF Stock News Headlines

June 1, 2023 | marketbeat.com
20 Best Healthcare Dividend Stocks to Invest in (AZNCF)
Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.
June 2, 2023 | tmcnet.com
AESOP Technology Announces Collaboration with AstraZeneca Taiwan on Medigator: Advancing Shared Decision-Making in Precision Medicine
June 2, 2023 | Legacy Research (Affiliate) (Ad)
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
June 2, 2023 | marketwatch.com
AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers
June 2, 2023 | msn.com
AstraZeneca announces new drug to treat lung and liver cancers now available in the UAE
June 1, 2023 | thetimes.co.uk
AstraZeneca prostate cancer treatment wins US approval
June 1, 2023 | msn.com
Pharma giant AstraZeneca to halt development of a treatment for Crohn's disease
June 1, 2023 | marketwatch.com
AstraZeneca Says US Approved Lynparza as a Prostate Cancer Treatment
June 2, 2023 | Stocks To Trade (Ad)
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
June 1, 2023 | marketwatch.com
AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program
June 1, 2023 | msn.com
AstraZeneca gains US approval for prostate cancer combo treatment
May 27, 2023 | msn.com
AstraZeneca aids government in fight vs kidney disease
May 26, 2023 | finance.yahoo.com
AstraZeneca PLC: Reaffirming BUY; strong product pipeline
May 26, 2023 | lse.co.uk
TOP NEWS: AstraZeneca's Ultomiris wins another approval in Japan
May 26, 2023 | msn.com
AstraZeneca announces good results from endometrial cancer trial
May 26, 2023 | lse.co.uk
AstraZeneca's Imfinzi plus Lynparza effective for endometrial cancer
May 26, 2023 | markets.businessinsider.com
AstraZeneca Reports Positive Results From DUO-E Phase III Trial - Quick Facts
May 25, 2023 | msn.com
AstraZeneca: Think Medium-To-Long Term
May 25, 2023 | businesswire.com
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
May 22, 2023 | msn.com
1 world-beating FTSE 100 share I’d buy today and it’s not AstraZeneca or National Grid
May 21, 2023 | msn.com
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
May 19, 2023 | news.yahoo.com
An AstraZeneca executive said the quiet part about China out loud
May 19, 2023 | msn.com
UPDATE 1-AstraZeneca will seek to "love the Communist Party" - China boss
May 19, 2023 | msn.com
AstraZeneca will seek to "love the Communist Party", its China boss says
May 17, 2023 | marketwatch.com
AstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In Trial
May 17, 2023 | americanbankingnews.com
AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Down 9.5% in April
May 16, 2023 | msn.com
AstraZeneca to leave leading U.S. drug lobby group
See More Headlines

AZNCF Price History

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals: Major
Sub-Industry
N/A
Sector
Health Technology
Current Symbol
OTCMKTS:AZNCF
CUSIP
N/A
CIK
901832
Web
N/A
Phone
442037495000
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
179.02
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Pascal Soriot
    Chief Executive Officer & Executive Director
  • Pam P. Cheng
    Executive VP-Operations & Information Technology
  • Aradhana Sarin
    Chief Financial Officer & Executive Director
  • Menelas NICOLAS Pangalos
    EVP-Biopharmaceuticals Research & Development
  • Cindy L. Hoots
    Chief Digital & Information Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













AZNCF Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZNCF shares.
View AZNCF analyst ratings or view top-rated stocks.

How have AZNCF shares performed in 2023?

AstraZeneca's stock was trading at $139.28 at the start of the year. Since then, AZNCF shares have increased by 4.9% and is now trading at $146.08.
View the best growth stocks for 2023 here.

Are investors shorting AstraZeneca?

AstraZeneca saw a decrease in short interest in April. As of April 30th, there was short interest totaling 502,800 shares, a decrease of 9.5% from the April 15th total of 555,700 shares. Based on an average daily trading volume, of 21,500 shares, the short-interest ratio is currently 23.4 days.
View AstraZeneca's Short Interest.

Is AstraZeneca a good dividend stock?

AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

What is AstraZeneca's stock symbol?

AstraZeneca trades on the OTCMKTS under the ticker symbol "AZNCF."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different institutional and retail investors. Top institutional investors include Boston Common Asset Management LLC (0.00%) and Vigilant Capital Management LLC (0.00%).

How do I buy shares of AstraZeneca?

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZNCF stock can currently be purchased for approximately $146.08.

How can I contact AstraZeneca?

The company can be reached via phone at 442037495000.

This page (OTCMKTS:AZNCF) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -